- Home
- TTGT vs SION Comparison
TTGT vs SION Comparison
Compare TTGT & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- SION
- Stock Information
- Founded
- TTGT 1999
- SION 2019
- Country
- TTGT United States
- SION United States
- Employees
- TTGT N/A
- SION N/A
- Industry
- TTGT Telecommunications Equipment
- SION
- Sector
- TTGT Telecommunications
- SION
- Exchange
- TTGT Nasdaq
- SION NYSE
- Market Cap
- TTGT 598.8M
- SION 564.4M
- IPO Year
- TTGT 2007
- SION 2025
- Fundamental
- Price
- TTGT $6.82
- SION $14.49
- Analyst Decision
- TTGT Buy
- SION Strong Buy
- Analyst Count
- TTGT 6
- SION 1
- Target Price
- TTGT $19.33
- SION $32.00
- AVG Volume (30 Days)
- TTGT 496.5K
- SION 124.0K
- Earning Date
- TTGT 08-07-2025
- SION 05-12-2025
- Dividend Yield
- TTGT N/A
- SION N/A
- EPS Growth
- TTGT N/A
- SION N/A
- EPS
- TTGT N/A
- SION N/A
- Revenue
- TTGT $284,897,000.00
- SION N/A
- Revenue This Year
- TTGT $79.55
- SION N/A
- Revenue Next Year
- TTGT N/A
- SION N/A
- P/E Ratio
- TTGT N/A
- SION N/A
- Revenue Growth
- TTGT 13.01
- SION N/A
- 52 Week Low
- TTGT $6.51
- SION $7.26
- 52 Week High
- TTGT $33.08
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- TTGT 40.38
- SION N/A
- Support Level
- TTGT $6.51
- SION N/A
- Resistance Level
- TTGT $7.26
- SION N/A
- Average True Range (ATR)
- TTGT 0.70
- SION 0.00
- MACD
- TTGT -0.02
- SION 0.00
- Stochastic Oscillator
- TTGT 13.54
- SION 0.00
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.